S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Grifols, S.A. stock logo
GRFS
Grifols
$6.58
-2.9%
$7.21
$5.30
$12.15
N/A0.563.02 million shs1.46 million shs
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$58.70
$58.82
$27.30
$64.41
$4.12B0.772.76 million shsN/A
MyoKardia, Inc. stock logo
MYOK
MyoKardia
$224.91
$224.61
$42.65
$225.00
$11.99B1.84752,969 shsN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$71.37
-0.3%
$74.54
$53.12
$77.72
$11.91B0.58195,413 shs141,889 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$117.89
+0.5%
$126.97
$55.25
$159.89
$11.07B0.94996,662 shs546,120 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Grifols, S.A. stock logo
GRFS
Grifols
-2.95%-5.60%+8.76%-2.52%-12.62%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00%0.00%0.00%-0.20%+40.26%
MyoKardia, Inc. stock logo
MYOK
MyoKardia
0.00%0.00%0.00%0.00%0.00%
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
-0.38%-1.69%-5.42%+4.69%+18.28%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
+0.51%-6.67%-4.90%+0.93%-6.10%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Grifols, S.A. stock logo
GRFS
Grifols
3.4482 of 5 stars
2.85.00.00.02.00.03.8
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.1644 of 5 stars
1.10.00.04.70.00.00.6
MyoKardia, Inc. stock logo
MYOK
MyoKardia
N/AN/AN/AN/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
1.5716 of 5 stars
2.05.01.70.00.60.01.9
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4.8682 of 5 stars
4.44.00.04.22.22.51.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Grifols, S.A. stock logo
GRFS
Grifols
1.67
Reduce$10.5059.57% Upside
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
2.21
Hold$60.002.21% Upside
MyoKardia, Inc. stock logo
MYOK
MyoKardia
N/AN/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
2.00
Hold$80.0012.09% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.80
Moderate Buy$158.3834.34% Upside

Current Analyst Ratings

Latest MYOK, MRTX, GRFS, SRPT, and RDY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/12/2024
Grifols, S.A. stock logo
GRFS
Grifols
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Sell
3/1/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$164.00 ➝ $167.00
2/29/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$128.00
2/29/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$151.00 ➝ $157.00
2/29/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$224.00
2/29/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$160.00 ➝ $172.00
2/29/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$141.00 ➝ $185.00
2/29/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$169.00 ➝ $166.00
2/20/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetIn-Line ➝ In-Line$108.00 ➝ $138.00
2/20/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$224.00
2/16/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$140.00 ➝ $169.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Grifols, S.A. stock logo
GRFS
Grifols
$7.13BN/A$0.79 per share8.29$12.61 per shareN/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$12.44M331.01N/AN/A$17.31 per share3.39
MyoKardia, Inc. stock logo
MYOK
MyoKardia
$33.56M357.36N/AN/A$8.79 per share25.59
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$2.99B3.98$4.23 per share16.88$16.87 per share4.23
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.24B8.90N/AN/A$9.19 per share12.83

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Grifols, S.A. stock logo
GRFS
Grifols
$131.34MN/A0.004.840.261.84%1.73%0.66%N/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/A
MyoKardia, Inc. stock logo
MYOK
MyoKardia
-$276.21M-$4.38N/AN/AN/AN/A-47.99%-42.42%N/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$548M$3.7918.8317.321.7719.26%20.97%15.19%5/8/2024 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$535.98M-$6.12N/A14.55N/A-43.11%-18.97%-4.65%5/7/2024 (Estimated)

Latest MYOK, MRTX, GRFS, SRPT, and RDY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/28/2024Q4 23
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$0.03$0.47+$0.50$0.47$387.18 million$396.80 million    
1/31/202412/31/2023
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$0.88$0.99+$0.11$0.99$827.81 million$867.00 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Grifols, S.A. stock logo
GRFS
Grifols
N/AN/AN/AN/AN/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/AN/AN/AN/AN/A
MyoKardia, Inc. stock logo
MYOK
MyoKardia
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$0.410.57%+42.53%10.82%4 Years
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Grifols, S.A. stock logo
GRFS
Grifols
1.24
2.83
1.32
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A
7.54
7.40
MyoKardia, Inc. stock logo
MYOK
MyoKardia
N/A
21.03
21.03
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
0.02
2.55
1.90
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1.32
3.95
3.45

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Grifols, S.A. stock logo
GRFS
Grifols
N/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A
MyoKardia, Inc. stock logo
MYOK
MyoKardia
N/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
14.02%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
Grifols, S.A. stock logo
GRFS
Grifols
0.19%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
3.26%
MyoKardia, Inc. stock logo
MYOK
MyoKardia
4.30%
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
2.00%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Grifols, S.A. stock logo
GRFS
Grifols
26,314N/AN/AOptionable
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
58770.15 million67.86 millionOptionable
MyoKardia, Inc. stock logo
MYOK
MyoKardia
31853.32 millionN/AOptionable
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
25,863166.88 million163.54 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,31493.90 million86.95 millionOptionable

MYOK, MRTX, GRFS, SRPT, and RDY Headlines

SourceHeadline
Mirae Asset Global Investments Co. Ltd. Sells 52,815 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Mirae Asset Global Investments Co. Ltd. Sells 52,815 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
marketbeat.com - April 16 at 5:04 AM
6,137 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Purchased by WCM Investment Management LLC6,137 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Purchased by WCM Investment Management LLC
marketbeat.com - April 15 at 7:31 AM
RSI Alert: Sarepta Therapeutics (SRPT) Now OversoldRSI Alert: Sarepta Therapeutics (SRPT) Now Oversold
nasdaq.com - April 15 at 12:19 AM
Allspring Global Investments Holdings LLC Sells 80,841 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Allspring Global Investments Holdings LLC Sells 80,841 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
marketbeat.com - April 14 at 5:37 AM
10 Unstoppable Stocks That Will Make You Richer10 Unstoppable Stocks That Will Make You Richer
finance.yahoo.com - April 13 at 10:21 PM
Sapient Capital LLC Takes $978,000 Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Sapient Capital LLC Takes $978,000 Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
marketbeat.com - April 13 at 7:45 AM
Pfizer: The Market Is WrongPfizer: The Market Is Wrong
seekingalpha.com - April 11 at 5:17 PM
Sarepta Therapeutics: Growth Trajectory Alters Trading StrategySarepta Therapeutics: Growth Trajectory Alters Trading Strategy
seekingalpha.com - April 11 at 7:16 AM
Sarepta Therapeutics: A Buy Recommendation Amidst Undervaluation and Growth Potential for ElevidysSarepta Therapeutics: A Buy Recommendation Amidst Undervaluation and Growth Potential for Elevidys
markets.businessinsider.com - April 10 at 9:35 AM
Sarepta Therapeutics: Another Hold Call Ahead Of Some Key CatalystsSarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts
seekingalpha.com - April 8 at 4:11 PM
Why Sareptas First-Quarter Report Is Already Dead In The Water: AnalystWhy Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
finance.yahoo.com - April 8 at 3:22 PM
RBC sees Sareptas Elevidys remaining on market: reportRBC sees Sarepta's Elevidys remaining on market: report
msn.com - April 7 at 6:17 PM
2 Biotech Stocks to Buy Hand Over Fist in April2 Biotech Stocks to Buy Hand Over Fist in April
fool.com - April 6 at 8:45 AM
China Universal Asset Management Co. Ltd. Purchases 8,427 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)China Universal Asset Management Co. Ltd. Purchases 8,427 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
marketbeat.com - April 5 at 10:20 AM
Buy Rating on Sarepta Therapeutics Amidst Anticipated Drug Approval and Market PotentialBuy Rating on Sarepta Therapeutics Amidst Anticipated Drug Approval and Market Potential
markets.businessinsider.com - April 5 at 4:06 AM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
marketbeat.com - April 1 at 2:16 AM
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com - March 29 at 4:00 PM
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
zacks.com - March 29 at 12:36 PM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Assenagon Asset Management S.A.Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Assenagon Asset Management S.A.
marketbeat.com - March 26 at 2:59 PM
Trial results for Dravet drug spurs stock surge at Bedford biotechTrial results for Dravet drug spurs stock surge at Bedford biotech
bizjournals.com - March 26 at 11:44 AM
A Comprehensive Look at Sareptas Growth and InnovationA Comprehensive Look at Sarepta's Growth and Innovation
finance.yahoo.com - March 25 at 7:14 PM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Vanguard Group Inc.Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Vanguard Group Inc.
marketbeat.com - March 20 at 4:56 AM
SRPT Jun 2024 80.000 callSRPT Jun 2024 80.000 call
ca.finance.yahoo.com - March 19 at 7:07 PM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Stephen Mayo Sells 3,135 SharesSarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Stephen Mayo Sells 3,135 Shares
insidertrades.com - March 16 at 9:12 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Grifols logo

Grifols

NASDAQ:GRFS
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Mirati Therapeutics logo

Mirati Therapeutics

NASDAQ:MRTX
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
MyoKardia logo

MyoKardia

NASDAQ:MYOK
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Dr. Reddy

Dr. Reddy's Laboratories

NYSE:RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Sarepta Therapeutics logo

Sarepta Therapeutics

NASDAQ:SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.